For example, EML4 is the most frequent fusion partner for ALK, but it is very rarely translocated with RET, ROS1 or NTRK1; likewise, CCDC6-RET and CD74-ROS1 fusions are frequently found in NSCLC patients, but CCDC6 fusion with ALK or ROS1 and CD74 fusion with ALK have never been described29,37–39 (Supplementary Fig. 10d–g). Here, RET is linked to non-small cell lung carcinoma.